<div id="readability-page-1"><div><p>Johnson &amp; Johnson announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib), during the 31st Annual AF Symposium in Boston. Initial results for 12-month outcomes across the 30-patient pilot cohort show investigators achieved 100% acute procedural success with no procedure-associated adverse events, while 56.7% of cases were performed with zero fluoroscopy and 90% of patients achieved primary effectiveness at 12 months. OMNY-AF is a prospective, single-arm, multi-center clinical trial conducted across more than 40 sites in the U.S. and Australia.</p><p>The study pairs the OMNYPULSE Catheter, a 12 mm large-tip focal catheter featuring contact-force sensing and bipolar, biphasic pulse delivery with the TRUPULSE Generator. This integrated design combines precise mapping, controlled energy delivery and live feedback through the PF index on the CARTO 3 System. The OMNYPULSE Platform is not currently approved in any region of the world.</p><p>Alongside the OMNY-AF data, Johnson &amp; Johnson is highlighting new findings related to the VARIPULSE Platform. Data presented by Andrea Natale, M.D.2, and simultaneously published in JACC Clin Electrophysiology, by Moussa Mansour, M.D.3 examined the incidence of neurovascular events following the workflow enhancements and the introduction of an optimized irrigation flow rate. Notably, the platform sustained a low neurovascular event rate of 0.22% in 6,811 patients after implementation of both workflow enhancements and the updated irrigation rate.</p><p>Additional VARIPULSE Platform data presented at AF Symposium adds to the growing body of evidence underscoring the platform's consistent and favorable safety profile across a range of clinical and real-world settings, including: VARISURE Safety survey data presented by Christopher Porterfield, M.D.4: Early results from this physician survey on 850 procedures indicated low complication rates with a 1.9% rate of primary adverse events, a 0.2% incidence of neurovascular events and no reported cases of coronary spasm or death. Same-day discharge was achieved in 87.9% of patients. REAL AF registry analysis presented by Mohammad-Ali Jazayeri, M.D.5: Results from the REAL AF registry showed excellent acute safety outcomes of the VARIPULSE Catheter, with a low overall acute safety event rate of 0.5% with no neurovascular events, high rates of same-day discharge and no observed differences in safety outcomes across AFib classifications.</p><p>Irrigation Flow Optimization research presented by Fengwei Zou, M.D.6: Preclinical data demonstrated parity between the 4 mL/min and 30 mL/min irrigation rates in microbubble generation, hemolysis and lesion depth when using the VARIPULSE catheter, while confirming that higher irrigation significantly reduced electrode surface heating.</p></div></div>

ARKG

<p>Johnson & Johnson presented 12-month pilot data from the OMNY-AF study at the 31st Annual AF Symposium, showcasing the investigational OMNYPULSE Platform for treating symptomatic paroxysmal atrial fibrillation (AFib). The study reported 100% acute procedural success with no adverse events in a 30-patient cohort. Additionally, findings on the VARIPULSE Platform highlighted a low neurovascular event rate of 0.22% in 6,811 patients, emphasizing its favorable safety profile. The study involved over 40 sites in the U.S. and Australia, but the OMNYPULSE Platform is not yet approved globally.</p>

marketscreener

iShares Global Healthcare

iShares US Medical Devices

Health Care Select Sector SPDR

Johnson & Johnson

SPDR S&P Health Equip

Ark Genomic Revolution ETF

iShares US Pharma

VG Health

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium